Asia Pacific Radiopharmaceuticals Market Growth, Size, Trends & Analysis 2034

Asia Pacific Radiopharmaceuticals Market Growth, Size, Trends Analysis - By Product, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Published: Jul-2025 Report ID: HLCA25208 Pages: 1 - 255 Formats*:     
Category : Healthcare
Asia Pacific Radiopharmaceuticals Market Introduction and Overview 

According to SPER Market Research, the Asia Pacific Radiopharmaceuticals Market is estimated to reach USD 5.89 billion by 2034 with a CAGR of 10.76%.

The report includes an in-depth analysis of the Asia Pacific Radiopharmaceuticals Market, including market size and trends, product mix, Applications, and supplier analysis.The Radiopharmaceuticals Market was valued at USD 2.12 billion in 2024 and is expected to grow at a CAGR of 10.76% from 2025 to 2034. The rising frequency of chronic diseases such as cancer and cardiovascular disease has increased the need for enhanced diagnostic and therapeutic options.  Radiopharmaceuticals, which are essential in nuclear medicine for imaging and treatment, are becoming more popular due to their efficacy.
By Application Insights
The urology sector had the greatest market share, owing to the high prevalence of urological illnesses, such as prostate cancer, which is one of the most frequent malignancies among males in the region.  Radiopharmaceuticals are widely utilised in the detection and treatment of prostate cancer, particularly with PET/CT scans and targeted radionuclide therapy.
The endocrine tumour segment is predicted to rise significantly throughout the forecast period, owing to the rising incidence of endocrine-related tumours and advances in nuclear medicine.  The introduction of innovative radiopharmaceuticals that target specific endocrine tumour indicators has increased diagnostic accuracy and therapeutic success.  Furthermore, the growing emphasis on personalised medicine and targeted therapeutics is accelerating the growth of this category.

By End User Insights
The diagnostic centres segment is estimated to develop due to rising demand for specialised diagnostic services and the rising prevalence of chronic diseases that necessitate improved imaging techniques for precise diagnosis. Diagnostic centres are becoming increasingly popular due to their capacity to provide targeted and efficient diagnostic services, generally with shorter wait times than hospitals. The implementation of cutting-edge imaging technologies in these centres, coupled with the increased awareness of the benefits of early disease identification, is driving the need for radiopharmaceuticals.

Regional Insights
Japan dominated the market due to extensive research and development efforts in the pharmaceutical sector. The government's emphasis on education and research, notably in healthcare technology and services, has aided this progress.  Japan is investing heavily in radiopharmaceutical research and development, including the formation of specialised research institutes and centres, as well as financing for AI-related projects. 

    

Market Competitive Landscape
The Asia Pacific Radiopharmaceuticals Market is dominated by established players such as ANSTO, Bracco, Cardinal Health, Eckert & Ziegler, ECZACIBAÅžI-MONROL as well as a number of small and medium-sized companies. Advanced R&D, strict regulatory compliance, and consistent isotope production have helped to establish dominance. Their global reach, cutting-edge infrastructure, and strategic alliances allow for efficient distribution and innovation. These companies offer constant quality and availability, addressing the expanding need for diagnostics and cancer therapy throughout global healthcare systems.

Recent Developments:
Full-Life Technologies and SK Biopharmaceuticals formed a partnership in July 2024 to develop its FL-091 radiopharmaceutical molecule into a global anti-cancer medication.  The firms struck a USD 571.5 million licensing agreement, giving SK Biopharmaceuticals the worldwide rights to develop and commercialise the revolutionary medication.
In May 2024, Novartis announced a significant expansion of its relationship with PeptiDream, investing USD 180 million up front to strengthen its radioligand treatment (RLT) portfolio.  The firms will collaborate to create therapeutic and diagnostic RLT solutions using PeptiDream’ s patented Peptide Discovery Platform System.  This method, which was previously used for peptide-drug conjugates, will now be used to find and optimise macrocyclic peptides for conjugation to radionuclides against targets chosen by Novartis.

Scope of the report:
 Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
 Forecast period 2025-2034
Segments coveredProduct, By Application, By End User
Regions covered
Japan, China, India, Singapore, Australia, South Korea, New Zealand, Thailand, Philippines
Companies Covered
Nordion Inc, Bracco, IRE - IRE ELiT - BE, NTP, ANSTO, ECZACIBAÅžI-MONROL, Lantheus, Eckert & Ziegler, Mallinckrodt company, Cardinal Health.

Key Topics Covered in the Report
  • Asia Pacific Radiopharmaceuticals Market Size (FY’2021-FY’2034)
  • Overview of Asia Pacific Radiopharmaceuticals Market
  • Segmentation of Asia Pacific Radiopharmaceuticals Market by Product (Diagnostics, Therapeutics)
  • Segmentation of Asia Pacific Radiopharmaceuticals Market by Application (Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Endocrine Tumor, Pulmonary Scans, Urology, Others)
  • Segmentation of Asia Pacific Radiopharmaceuticals Market by End User (Hospitals, Diagnostic Centres, Others)
  • Statistical Snap of Asia Pacific Radiopharmaceuticals Market
  • Expansion Analysis of Asia Pacific Radiopharmaceuticals Market
  • Problems and Obstacles in Asia Pacific Radiopharmaceuticals Market
  • Competitive Landscape in the Asia Pacific Radiopharmaceuticals Market
  • Details on Current Investment in Asia Pacific Radiopharmaceuticals Market
  • Competitive Analysis of Asia Pacific Radiopharmaceuticals Market
  • Prominent Players in the Asia Pacific Radiopharmaceuticals Market
  • SWOT Analysis of Asia Pacific Radiopharmaceuticals Market
  • Asia Pacific Radiopharmaceuticals Market Future Outlook and Projections (FY’2025-FY’2034)
  • Recommendations from Analyst

1.Introduction

1.1.Scope of the report

1.2.Market segment analysis


2.Research Methodology

2.1.Research data source

2.1.1.Secondary Data

2.1.2.Primary Data

2.1.3.SPERs internal database

2.1.4.Premium insight from KOLs

2.2.Market size estimation

2.2.1.Top-down and Bottom-up approach

2.3.Data triangulation


3.Executive Summary


4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis

4.1.1.Drivers

4.1.2.Restraints

4.1.3.Opportunities

4.1.4.Challenges


5.Market variable and outlook

5.1.SWOT Analysis

5.1.1.Strengths

5.1.2.Weaknesses

5.1.3.Opportunities

5.1.4.Threats

5.2.PESTEL Analysis

5.2.1.Political Landscape

5.2.2.Economic Landscape

5.2.3.Social Landscape

5.2.4.Technological Landscape

5.2.5.Environmental Landscape

5.2.6.Legal Landscape

5.3.PORTERs Five Forces 

5.3.1.Bargaining power of suppliers

5.3.2.Bargaining power of buyers

5.3.3.Threat of Substitute

5.3.4.Threat of new entrant

5.3.5.Competitive rivalry

5.4.Heat Map Analysis


6.Competitive Landscape

6.1.Asia Pacific Radiopharmaceuticals Market Manufacturing Base Distribution, Sales Area, Product Type 

6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Asia Pacific Radiopharmaceuticals Market 


7.Asia Pacific Radiopharmaceuticals Market, By Product (USD Million) 2021-2034

7.1.Diagnostics

7.2.Therapeutics


8.Asia Pacific Radiopharmaceuticals Market, By Application (USD Million) 2021-2034

8.1.Cardiology

8.2.Neurology

8.3.Oncology

8.4.Thyroid

8.5.Lymphoma

8.6.Endocrine Tumor

8.7.Pulmonary Scans

8.8.Urology

8.9.Others


9.Asia Pacific Radiopharmaceuticals Market, By End User (USD Million) 2021-2034

9.1.Hospitals

9.2.Diagnostic Centres

9.3.Others

          

10.Asia Pacific Radiopharmaceuticals Market, (USD Million) 2021-2034

10.1.Asia Pacific Radiopharmaceuticals Market Size and Market Share


11.Asia Pacific Radiopharmaceuticals Market, By Region, (USD Million) 2021-2034

11.1.Japan

11.2.China

11.3.India

11.4.Singapore

11.5.Australia

11.6.South Korea

11.7.New Zealand

11.8.Thailand

11.9.Philippines


12.Company Profile

12.1.ANSTO

12.1.1.Company details

12.1.2.Financial outlook

12.1.3.Product summary 

12.1.4.Recent developments

12.2.Bracco

12.2.1.Company details

12.2.2.Financial outlook

12.2.3.Product summary 

12.2.4.Recent developments

12.3.Cardinal Health

12.3.1.Company details

12.3.2.Financial outlook

12.3.3.Product summary 

12.3.4.Recent developments

12.4.Eckert & Ziegler

12.4.1.Company details

12.4.2.Financial outlook

12.4.3.Product summary 

12.4.4.Recent developments

12.5.ECZACIBAÅžI-MONROL

12.5.1.Company details

12.5.2.Financial outlook

12.5.3.Product summary 

12.5.4.Recent developments

12.6.IRE - IRE ELiT - BE

12.6.1.Company details

12.6.2.Financial outlook

12.6.3.Product summary 

12.6.4.Recent developments

12.7.Lantheus

12.7.1.Company details

12.7.2.Financial outlook

12.7.3.Product summary 

12.7.4.Recent developments

12.8.Mallinckrodt Company

12.8.1.Company details

12.8.2.Financial outlook

12.8.3.Product summary 

12.8.4.Recent developments

12.9.Nordion Inc

12.9.1.Company details

12.9.2.Financial outlook

12.9.3.Product summary 

12.9.4.Recent developments

12.10.NTP

12.10.1.Company details

12.10.2.Financial outlook

12.10.3.Product summary 

12.10.4.Recent developments

12.11.Others


13.Conclusion

14.List of Abbreviations

15.Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report
Asia Pacific Radiopharmaceuticals Market size from 2025. The Market is expected to reach USD 5.89 by 2034, at a CAGR of 10.76% during the forecast period.
Asia Pacific Radiopharmaceuticals Market CAGR of 10.76% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Asia Pacific Radiopharmaceuticals Market size is USD 5.89 from 2025 to 2034.
Asia Pacific Radiopharmaceuticals Market covered Product, By Application, By End User
The North America is anticipated to have the highest Market share in the Asia Pacific Radiopharmaceuticals Market .
" Nordion Inc, Bracco, IRE - IRE ELiT - BE, NTP, ANSTO, ECZACIBAÅžI-MONROL, Lantheus, Eckert & Ziegler, Mallinckrodt company, Cardinal Health. "
The report includes an in-depth analysis of the Asia Pacific Radiopharmaceuticals Market, including market size and trends, product mix, Applications, and supplier analysis.
Asia Pacific Radiopharmaceuticals Market is projected to reach USD 5.89 by 2034, growing at a CAGR of 10.76 % during the forecast period.
PLACE AN ORDER
Year End Discount
  • 15 % off
     
    $ 3400
  • 20 % off
             
    $ 4520
  • 25 % off
         
    $ 5650
Sample Report
Download Free Sample Pages
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
   +1-512-717-7719
India:
   +91-959-915-8047
Email:
   [email protected]
100% Secure Payment
SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues
Related Reports

Global Nanorobots Market Growth, Size, Trends Analysis – By Type, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Global Transthyretin Amyloidosis Treatment Market Growth, Size, Trends Analysis- By Therapy, By Type, By Disease, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Global Opioid Induced Constipation Drugs Market Growth, Size, Trends Analysis - By Drug Class, By Prescription, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

U.S. Eye Care Market Size- By Product, By Mode of Purchase, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Global Viral Inactivation Market Growth, Size, Trends Analysis - By Product & Service, By Application, By End-use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Global Teleradiology Market Growth, Size, Trends Analysis - By Product, By Report Type, By End-use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Global Parkinson’s Disease Treatment Market Growth, Size, Trends Analysis – By Drug Class, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Have a glance of the Report

  Download Free Sample

Looking for Customization?

 Customization Request

Have a Question?

 Reach Our Analysis Team

COVID-19 impact analysis?

 Request Analysis

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.

SPER-Astellas Pharma
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-IQVIA
SPER-Mitsubishi Logistics
SPER-PACCOR
SPER-Macmillan Education
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-SAPTCA
SPER-Straumann
SPER-MENARINI Silicon Biosystems
SPER-IPSOS
SPER-Heineken